Broad Spectrum Cannabidiol
Phase 2Small molecule
Broad Spectrum Cannabidiol is one of 9 small molecule programs targeting Cannabis Use. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
7 competitors in Cannabis Use
#DrugCompanyPhaseTrials
1Mounjaro
Eli LillyApproved
Epidiolex
Jazz PharmaceuticalsPhase 2
Intuniv
PPromius Pharma, LLC
Phase 2
Broad Spectrum Cannabidiol
UUniversity of Colorado, Denver
Phase 2
Fscbd Cannabidiol
UUniversity of Colorado, Boulder
Phase 2
Bscbd Cannabidiol
UUniversity of Colorado, Boulder
Phase 2
Tetrahydrocannabinol
HHadassah Medical Organization
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Broad Spectrum Cannabidiol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Colorado, Denver